OTCMKTS:HLUYY - H. Lundbeck A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $107.42
  • Forecasted Upside: 437.09 %
  • Number of Analysts: 5
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$20.00
+0 (0.00%)

This chart shows the closing price for HLUYY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New H. Lundbeck A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLUYY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLUYY

Analyst Price Target is $107.42
▲ +437.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for H. Lundbeck A/S in the last 3 months. The average price target is $107.42, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 437.09% upside from the last price of $20.00.

This chart shows the closing price for HLUYY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in H. Lundbeck A/S. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/1/2022JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight40.00 ➝ 46.00
2/22/2022BarclaysLower Price Target200.00 ➝ 190.00
2/10/2022Credit Suisse GroupLower Price Target175.00 ➝ 163.00
1/4/2022JPMorgan Chase & Co.Lower Price Target250.00 ➝ 200.00
11/24/2021Berenberg BankInitiated CoverageBuy
10/7/2021Deutsche Bank AktiengesellschaftReiterated RatingSell
9/2/2021BarclaysReiterated RatingOverweight
8/20/2021Credit Suisse GroupReiterated RatingUnderperform
7/23/2021Deutsche Bank AktiengesellschaftInitiated CoverageSell$30.67
7/16/2021BarclaysReiterated RatingOverweight
6/16/2021BarclaysReiterated RatingOverweight
5/12/2021JPMorgan Chase & Co.Reiterated RatingOverweight
4/14/2021DanskeUpgradeHold ➝ Buy
3/26/2021Credit Suisse GroupReiterated RatingUnderperform
3/8/2021BarclaysReiterated RatingOverweight
2/12/2021Bank of AmericaUpgradeUnderperform ➝ Neutral
2/5/2021Credit Suisse GroupReiterated RatingUnderperform
2/5/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
11/6/2020UBS GroupReiterated RatingBuy
11/4/2020Credit Suisse GroupReiterated RatingUnderperform
10/16/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/13/2020BarclaysReiterated RatingOverweight
9/15/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral
8/21/2020AlphaValueDowngradeBuy
8/17/2020UBS GroupReiterated RatingBuy
8/14/2020Credit Suisse GroupReiterated RatingUnderperform
8/14/2020BarclaysReiterated RatingOverweight
3/4/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/14/2018BarclaysUpgradeEqual Weight ➝ Overweight
11/12/2018SVB LeerinkInitiated CoverageMarket Perform
5/3/2018DNB MarketsDowngradeBuy ➝ Sell
7/28/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
(Data available from 7/6/2017 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
H. Lundbeck A/S logo
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Read More

Today's Range

Now: $20.00
Low: $20.00
High: $20.00

50 Day Range

MA: $21.33
Low: $11.25
High: $24.80

52 Week Range

Now: $20.00
Low: $10.00
High: $32.32

Volume

93 shs

Average Volume

2,845 shs

Market Capitalization

$19.91 billion

P/E Ratio

N/A

Dividend Yield

0.98%

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of H. Lundbeck A/S?

The following equities research analysts have issued stock ratings on H. Lundbeck A/S in the last twelve months: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, and JPMorgan Chase & Co..
View the latest analyst ratings for HLUYY.

What is the current price target for H. Lundbeck A/S?

0 Wall Street analysts have set twelve-month price targets for H. Lundbeck A/S in the last year. Their average twelve-month price target is $107.42, suggesting a possible upside of 437.1%.
View the latest price targets for HLUYY.

What is the current consensus analyst rating for H. Lundbeck A/S?

H. Lundbeck A/S currently has 2 sell ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HLUYY, but not buy more shares or sell existing shares.
View the latest ratings for HLUYY.

How do I contact H. Lundbeck A/S's investor relations team?

H. Lundbeck A/S's physical mailing address is Ottiliavej 9 Valby, Copenhagen G7, 2500. The company's listed phone number is (453) 630-1311 and its investor relations email address is [email protected] The official website for H. Lundbeck A/S is www.lundbeck.com. Learn More about contacing H. Lundbeck A/S investor relations.